Volume 24, Issue 5, Pages (May 2006)

Slides:



Advertisements
Similar presentations
Volume 42, Issue 2, Pages (February 2015)
Advertisements

Volume 28, Issue 5, Pages (May 2008)
Volume 25, Issue 6, Pages (December 2006)
Volume 28, Issue 2, Pages (February 2008)
Volume 45, Issue 5, Pages (November 2016)
Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3  Rashu B. Seth, Lijun Sun, Chee-Kwee.
Volume 24, Issue 5, Pages (May 2006)
Volume 35, Issue 4, Pages (October 2011)
Volume 41, Issue 6, Pages (December 2014)
Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission  Yongjun Tian,
Volume 10, Issue 10, Pages (March 2015)
Volume 40, Issue 3, Pages (March 2014)
Volume 11, Issue 4, Pages (October 1999)
Volume 35, Issue 3, Pages (September 2011)
Volume 47, Issue 3, Pages e6 (September 2017)
Volume 35, Issue 6, Pages (December 2011)
Volume 21, Issue 1, Pages (July 2004)
Brian Yordy, Norifumi Iijima, Anita Huttner, David Leib, Akiko Iwasaki 
Volume 150, Issue 3, Pages (August 2012)
Volume 8, Issue 6, Pages (December 2010)
Volume 8, Issue 5, Pages (November 2010)
Volume 29, Issue 4, Pages (October 2008)
Volume 34, Issue 6, Pages (June 2011)
Volume 24, Issue 3, Pages (March 2006)
Volume 47, Issue 4, Pages e3 (October 2017)
Volume 64, Issue 2, Pages (October 2016)
Volume 11, Issue 8, Pages (May 2015)
Volume 27, Issue 2, Pages (August 2007)
T Cell-Produced Transforming Growth Factor-β1 Controls T Cell Tolerance and Regulates Th1- and Th17-Cell Differentiation  Ming O. Li, Yisong Y. Wan, Richard.
Volume 35, Issue 3, Pages (September 2011)
Volume 12, Issue 1, Pages (July 2015)
TET3 Inhibits Type I IFN Production Independent of DNA Demethylation
Daniel B. Stetson, Ruslan Medzhitov  Immunity 
Volume 37, Issue 6, Pages (December 2012)
Volume 36, Issue 2, Pages (February 2012)
Volume 46, Issue 3, Pages (March 2017)
Glycogen Synthase Kinase 3β Regulates IRF3 Transcription Factor-Mediated Antiviral Response via Activation of the Kinase TBK1  Cao-Qi Lei, Bo Zhong, Yu.
Volume 37, Issue 2, Pages (August 2012)
Volume 34, Issue 3, Pages (March 2011)
Volume 4, Issue 4, Pages (April 1996)
Granulin Is a Soluble Cofactor for Toll-like Receptor 9 Signaling
Volume 28, Issue 4, Pages (April 2008)
Volume 22, Issue 2, Pages (February 2005)
Volume 30, Issue 3, Pages (March 2009)
Volume 9, Issue 5, Pages (May 2011)
Cell Type-Specific Involvement of RIG-I in Antiviral Response
Volume 24, Issue 3, Pages (March 2006)
Volume 17, Issue 6, Pages (June 2015)
Volume 36, Issue 4, Pages (April 2012)
Volume 9, Issue 4, Pages (April 2011)
Immune Response in Stat2 Knockout Mice
Volume 5, Issue 5, Pages (May 2009)
Volume 21, Issue 6, Pages (November 2017)
Volume 22, Issue 6, Pages (February 2018)
Volume 34, Issue 5, Pages (May 2011)
Yu-Hsin Chiu, John B. MacMillan, Zhijian J. Chen  Cell 
Volume 152, Issue 3, Pages (January 2013)
Volume 44, Issue 5, Pages (May 2016)
Volume 3, Issue 1, Pages (January 2013)
Volume 11, Issue 3, Pages (September 1999)
Volume 33, Issue 5, Pages (November 2010)
Volume 40, Issue 3, Pages (March 2014)
Volume 38, Issue 1, Pages (January 2013)
Volume 28, Issue 5, Pages (May 2008)
PU.1 Expression Delineates Heterogeneity in Primary Th2 Cells
Volume 24, Issue 1, Pages (January 2006)
Volume 14, Issue 2, Pages (August 2013)
TRAIL-R as a Negative Regulator of Innate Immune Cell Responses
Volume 36, Issue 6, Pages (June 2012)
Volume 11, Issue 6, Pages (June 2012)
Presentation transcript:

Volume 24, Issue 5, Pages 633-642 (May 2006) The Specific and Essential Role of MAVS in Antiviral Innate Immune Responses  Qinmiao Sun, Lijun Sun, Hong-Hsing Liu, Xiang Chen, Rashu B. Seth, James Forman, Zhijian J. Chen  Immunity  Volume 24, Issue 5, Pages 633-642 (May 2006) DOI: 10.1016/j.immuni.2006.04.004 Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 1 Generation of Mavs−/− Mice (A) Targeting strategy for deleting exon 2 from the ATG start codon to exon 3 of the Mavs locus by homologous recombination. Abbreviation: DTA, diphtheria toxin A. (B) Southern blotting analysis of BamH1-digested genomic DNA from the mouse tails using the 5′ probe as indicated in (A). (C) Immunoblot analysis of protein extracts from MEF cells of different genotypes using an antibody against mouse MAVS. Abbreviation: N.S., nonspecific. (D) Offspring from the breeding of Mavs+/− mice. Immunity 2006 24, 633-642DOI: (10.1016/j.immuni.2006.04.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 2 MAVS Is Required for Antiviral Innate Immune Responses in MEF Cells (A–C) MEF cells were incubated with Sendai virus (SeV), LPS, or poly(I:C) for 16 hr, and the culture supernatants were harvested for ELISA analyses to measure the production of IFN-α, IFN-β, and IL-6 as indicated. Error bars represent standard deviations from the means of duplicated experiments. (D) MEF cells were infected with SeV for the indicated times and then cell lysates were separated on 9% polyacrylamide gels under nondenaturing conditions. The IRF3 dimer and monomer were detected by immunoblotting. Abbreviation: hpi, hours postinfection. (E and F) Electrophoretic mobility shift assays (EMSA) for NFκB DNA binding using whole-cell extracts from MEF cells infected with SeV or stimulated with LPS for the indicated times. The asterisks (∗) indicate nonspecific beads. (G) MEF cells were transfected with poly(I:C) for the indicated times and then cell extracts were prepared for analyses of IRF3 dimerization by native gel electrophoresis. (H) MEF cells were incubated with VSV-GFP at the indicated multiplicity of infection (MOI) for 24 hr, and infection of cells was visualized by fluorescent microscopy. Nomarski microscopy showed that less Mavs−/− cells were detected after VSV-GFP infection, an indication that these cells were more susceptible to viral killing. Immunity 2006 24, 633-642DOI: (10.1016/j.immuni.2006.04.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 3 MAVS Is Essential for Antiviral Innate Immune Responses in Macrophages (A–F) Bone marrow-derived macrophages (BMDMs) or peritoneal macrophages (Mϕs) were incubated with SeV, LPS, or poly(I:C) for 16 hr and then culture supernatants were collected for measurement of IFN-α, IFN-β, or IL-6 by ELISA as indicated. The asterisks (∗) indicate levels that were not detectable. Error bars represent standard deviations from the means of duplicated experiments. (G) Cell extracts from BMDMs infected with SeV for the indicated times were resolved by native gel electrophoresis and then analyzed by immunoblotting with an IRF3-specific antibody. (H) Cell extracts as described in (G) were incubated with γ-32P-ATP-labeled NFκB oligos and then resolved by native gel electrophoresis (EMSA). Abbreviation: N.S., nonspecific. Immunity 2006 24, 633-642DOI: (10.1016/j.immuni.2006.04.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 4 MAVS Is Not Required for Interferon Induction by Cytosolic DNA or Listeria Monocytogenes (A) MEF cells were transfected with poly(dA:dT) or poly(dI:dC) for 16 hr and then culture supernatants were harvested for measurement of IFN-β by ELISA. (B) MEF cells were transfected with 10 μg/ml of poly(dA:dT) DNA, and the cell lysates were resolved by native gel electrophoresis followed by immunoblotting with an IRF3 antibody (top). The same cell lysates were also analyzed for NFκB DNA binding by EMSA (bottom). Abbreviation: N.S., nonspecific. (C) Similar to (B), except that poly(dI:dC) was used to stimulate cells. (D and E) BMDMs were infected with Listeria monocytogenes (L.M.) for 16 hr, and the culture supernatants were harvested for measurement of IFN-β and IL-6 by ELISA. (F and G) MEF cells or peritoneal macrophages were infected with L.M. for 16 hr, and the induction of IL-6 was measured by ELISA. (H) Cell lysates from MEF cells infected with L.M. or SeV were resolved by native gel electrophoresis and then immunoblotted with an antibody against IRF3. Immunity 2006 24, 633-642DOI: (10.1016/j.immuni.2006.04.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 5 MAVS Is Essential for Interferon Induction in cDCs, but Not pDCs (A–C) cDCs were isolated from bone marrow cells after stimulation with GM-CSF. These cells were incubated with SeV (A–C), LPS, poly(I:C), or CpG DNA (C), and the production of IFN-α, IFN-β, and IL-6 was measured by ELISA. (D and E) pDCs were isolated from Flt-3L-stimulated bone marrow cells and purified by FACS. These cells were stimulated with SeV for 16 hr and then culture supernatants were harvested for measurement of IFN-α and IFN-β by ELISA. Error bars represent standard deviations from the means of duplicated experiments. Immunity 2006 24, 633-642DOI: (10.1016/j.immuni.2006.04.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 6 MAVS Is Required for Antiviral Immune Defense In Vivo (A) Wild-type (n = 7), Mavs+/− (n = 5), and Mavs−/− (n = 5) mice were infected with VSV-GFP (2 × 108 pfu) via tail vein injection. The sera were collected from the mice at different time points as indicated and used to measure viral titers by plaque assays. The error bars indicate the standard error of the mean (SEM). (B) Sera collected as in (A) were used for measurement of IFN-α and IFN-β by ELISA. The error bars indicate SEM. (C) Mavs+/+, Mavs+/−, and Mavs−/− mice (n = 6 for each genotype) were infected with wild-type VSV (Indiana strain; 5 × 107 pfu) via tail vein injection, and the survival of the mice was monitored for 5 weeks. The mice that survived the viral infections at 2 weeks remained alive after 5 weeks. Immunity 2006 24, 633-642DOI: (10.1016/j.immuni.2006.04.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 7 MAVS Is Required for Interferon Induction By Poly(I:C) In Vivo Wild-type (n = 5), Mavs+/− (n = 5), and Mavs−/− (n = 6) mice were injected intravenously with 200 μg of poly(I:C) and then sera were collected at indicated times for ELISA to measure the concentrations of IFN-α (A), IFN-β (B), and IL-6 (C). Littermates of 10- to 12-week-old mice were used for this experiment. The error bars indicate SEM. Immunity 2006 24, 633-642DOI: (10.1016/j.immuni.2006.04.004) Copyright © 2006 Elsevier Inc. Terms and Conditions